We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Pharm Gp | LSE:OXP | London | Ordinary Share | GB00B3LXPB43 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.45 | 1.55 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
06/9/2022 10:50 | Oxford Pharmascience Ltd has consolidated its share capital. Under the terms of the consolidation every 200,000 shares as at the close of business on 25 August 2022 were consolidated into 1 new share. Worthless as expected. Shame, but I made a lovely profit on the cash return. | eezymunny | |
08/3/2018 14:40 | Thanks Eezy. Who are the brokers? I'll put Barclays in touch with them. | mctmct | |
08/3/2018 13:08 | I have mine with 2 different brokers mctmct. Took a bit of time but they are there now. Note that they did a share consolidation (see companies house), 20 for 1 or something from memory, so you end up with less shares but an equivalent % ownership. I guess we'll be lucky if they're ever worth anything but you never know... | eezymunny | |
08/3/2018 11:59 | Has any OXP shareholder received any shares in OPL? I haven't and my stockbroker says that other brokers haven't either. It looks as though the corporate action was mishandled because the capital reorganisation, demerger and name change all came close together. I suggest that all OXP shareholders (now ABA shareholders) chase their brokers to locate their shares in OPL and let this BB know what they discover. | mctmct | |
20/11/2017 08:25 | >>>>Nick Rubens I would assume that if and when they de-merge, shareholders will get one share in each de-merged company for each share they currently own in OXP. Shareholders shouldn't have a problem with that, especially Woodford, as much of his life science SME portfolio is unquoted anyway. Today's news is of interest as it shows that not all EU regulators think alike. I don't think it really makes a lot of difference though, basically it gives them a route to market in Sweden and possibly elsewhere for a chewable or liquid taste mask formula with identical claims to Nurofen and generic ibuprofen tablets, i.e. there would be no claims differentiation and no claims regarding improved safety. However, it would be a relatively straightforward application requiring just the normal pharmaceutics package plus biostudy. | timbo003 | |
20/11/2017 08:20 | You do Nick. The shares will unlisted but you'll still own them. And the cash shell will have c. 1.6p/share in cash if my sums are right. | eezymunny | |
20/11/2017 08:12 | What happens to the part of the company that gets demerged and we end up with a cash shell. Who owns the demerged part? | nick rubens | |
16/11/2017 12:42 | Buying orders still being worked. Don't sell this too early. | carbon man | |
15/11/2017 19:04 | I would expect a holding rns with that large trade | john60566 | |
15/11/2017 18:16 | Big trades going through. Looks like the pro's are putting down the markers. Could be ?????? | carbon man | |
13/11/2017 10:50 | fyi British Bulls OXP.L OXFORD PHARMASCIENCE GROUP Last Signal: STAY LONG Last Pattern: BEARISH HARAMI CROSS Last Close: 1.3750 Change: +0.1750 Percent change +14.58% Signal Update Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 03/11/2017, 7 days ago, when the stock price was 1.2019. Since then OXP.L has risen by +14.40%. | carbon man | |
10/11/2017 15:23 | How certain is it to go through the EGM? | mctmct | |
10/11/2017 11:05 | Yes this is excellent. A cash shell with a lot of cash ....19 million....at a discount. Opps galore here. A buyer today myself today and think this is going to 2 p shortly | barnetpeter | |
10/11/2017 09:18 | At last, some good news for shareholders. It looks like Woodford and Griffiths had had enough. Lets hope that they now find a decent home for the remaining cash. | timbo003 | |
02/10/2017 12:05 | Yes you have timbo and I got out previously because of your warnings. Have traded this a couple of times since for a profit and I will be tempted to buy in again at about the 0.8 level because of the amount of cash held which is producing plenty of interest. But that will just be a punt on the hope the cash will be returned or a take over by a cash hungry company will take place. We can only hope the bod realise it is now game over. They have suspended operations which is encouraging in fact. | barnetpeter | |
02/10/2017 11:02 | >>>>bp I have been saying this for the last 3-4 years, I worked in the industry for 25 years on this sort of development, it was evident to me from the onset that this was a complete load of rubbish, it was just Marcel with a few stupid ideas and a load of shareholder's cash living the dream. | timbo003 | |
02/10/2017 10:33 | This is bad. Nothing really works. The company is now a cash shell with nothing viable. The good news is the cash is about 1.5 per share but there will be some costs in closing up the labs etc so I would guess about a net 1p per share or slightly more. Not a great buy at the moment ....only holding a small amount now at zero cost and will wait for development but would suggest this is a dangerous buy | barnetpeter | |
25/9/2017 16:02 | Now you know why | barnes4 | |
11/9/2017 23:34 | Now we have sellers. Any ideas? | carbon man | |
22/8/2017 18:16 | Do not be misled, All trades are shown on ADVFN today are BUYS not sales. This is ready to spike. | carbon man | |
10/8/2017 18:14 | Been watching this stock for months, with their cash balances, it looks like a bounce is due. Any ideas? | carbon man | |
18/7/2017 09:23 | Had to pay a premium at 1.7p... looking for a re-rate. | cantrememberthis2 | |
09/5/2017 13:32 | Indeed bp and shareholders should ensure that it is deployed wisely on projects which have a reasonable chance of success, rather then on Marcello's pipe dreams. | timbo003 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions